Latest:
Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL
Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Mark Agulnik, MD
Mark Agulnik, MD, is a medical oncologist with the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC
Latest:
Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions
In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.
John A. Livingston, MD, MS
John A. Livingston, MD, MS, is a clinician and researcher in the Department of Sarcoma Medical Oncology, of the Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center.
Latest:
Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma
John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.
Neelam Desai, MD
Neelam Desai, MD, is a breast medical oncologist and hematologist at the Atrium Health Levine Cancer Institute in North Carolina.
Latest:
Dr Desai on Research Informing Upfront CDK 4/6 Inhibitor Use in HR+/HER2– Breast Cancer
Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.
Benjamin Jon Golas, MD, FACS
Benjamin Jon Golas, MD, FACS, is regional chief of Surgical Oncology for Hackensack Meridian Health’s Central Region, surgical director of Oncology Services at Jersey Shore University Medical Center, vice chair of Surgery at Jersey Shore University Medical Center Cancer Surgery, and an associate professor of surgery at the Hackensack Meridian School of Medicine
Latest:
Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.
Raul Cordoba, MD, PhD
Latest:
Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) and Zanubrutinib Induces High Rate of Complete Remission for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Raul Cordoba, MD, PhD, presents results from the phase 1 study of sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma, highlighting a favorable safety profile with no tumor lysis syndrome or atrial fibrillation, and promising antitumor activity, including a 78% overall response rate and a 70% complete response rate at the recommended dose of 320 mg.
Benny Weksler, MD, MBA, FACS, FACCP
Latest:
Dr. Weksler on Addressing Disparities in Lung Cancer Care Delivery
Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.
Maggie Tibbitt
Latest:
Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical Cancer
Nicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.
Susana Banerjee
Latest:
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Professor Susana Banerjee presents the ENGOT-OV60/GOG-3052/RAMP 201 study, highlighting the efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer.
Prioty Islam, MD, MSc
Latest:
Dr Islam on the Limited Use of Ibrutinib in CLL
Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.
Sponsored by Sandoz
Latest:
Further Integrating Biosimilars into Oncology: The Role of WYOST (denosumab-bbdz) in Preventing Cancer-Related Skeletal Events with Bone Metastases from Solid Tumors
Cancer patients facing skeletal-related events may benefit from WYOST®, the first FDA-approved biosimilar for this condition, offering safe, effective, and more affordable treatment for bone complications.